---
document_datetime: 2024-02-15 14:14:47
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/besponsa-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: besponsa-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.4426942
conversion_datetime: 2025-12-28 02:08:27.800541
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BESPONSA

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                      |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------|
| II/0026              | Update of sections 4.2, 4.6, 4.8, 5.1 and 5.2 of the SmPC in order to update paediatric information based on final results from studies ITCC-059 (WI203581) and INO-Ped-ALL-1 (WI235086). Study WI203581 is a Phase 1/2, multicenter, European, multi-cohort, open-label study in pediatric patients (â‰¥1 and <18 years of age) with R/R CD22 -positive Acute Lymphoblastic Leukemia (ALL); and study | 14/12/2023                          |                                             | SmPC and PL                      | Please refer to Scientific Discussion Besponsa EMEA/H/C/004119/II/0026 and Besponsa EMEA/H/C/004119/P46/004. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | WI235086 is an open-label, multi-center Phase 1 study to assess safety and tolerability of InO in Japanese pediatric patients with R/R CD22-positive ALL. The Package Leaflet is updated accordingly. The MAH took also the opportunity to update the ATC code in section 5.1 and to implement some editorial changes in the PI. The RMP version 2.2 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                                  |                                                                                                                                                                                                                                                                        |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10659 /202212 | Periodic Safety Update EU Single assessment - inotuzumab ozogamicin                                                                                                                                                                                                                                                                                                                                                                                                                               | 06/07/2023 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| PSUSA/10659 /202112 | Periodic Safety Update EU Single assessment - inotuzumab ozogamicin                                                                                                                                                                                                                                                                                                                                                                                                                               | 07/07/2022 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| R/0023              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 16/12/2021 | 16/02/2022 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of BESPONSA in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10659 /202012 | Periodic Safety Update EU Single assessment - inotuzumab ozogamicin                                                                                                                                                                                                                                                                                                                                                                                                                               | 08/07/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| IAIN/0022           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                        | 31/05/2021 | 03/11/2021 | Annex II and PL                  |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| II/0020/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS   | 06/05/2021   | n/a        |                                  |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------|
| IB/0019/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                | 16/10/2020   | 03/11/2021 | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/10659 /201912 | Periodic Safety Update EU Single assessment - inotuzumab ozogamicin                                                                                                                                                                                                                                                                                                                                                    | 09/07/2020   | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0018             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                 | 23/04/2020   | n/a        |                                  |                                   |
| PSUSA/10659         | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                          | 16/01/2020   | n/a        |                                  | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| /201906             | inotuzumab ozogamicin                                                                                                                                                                                                                  |            |            |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------|
| IAIN/0016           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 11/12/2019 | 23/07/2020 | Annex II and PL                   |
| IB/0014             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                 | 26/11/2019 | n/a        |                                   |
| IB/0013             | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                 | 20/11/2019 | n/a        |                                   |
| N/0015              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                       | 13/11/2019 | 23/07/2020 | PL                                |
| IB/0011             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                    | 21/08/2019 | 23/07/2020 | SmPC and PL                       |
| PSUSA/10659 /201812 | Periodic Safety Update EU Single assessment - inotuzumab ozogamicin                                                                                                                                                                    | 11/07/2019 | n/a        | PRAC Recommendation - maintenance |
| PSUSA/10659 /201806 | Periodic Safety Update EU Single assessment - inotuzumab ozogamicin                                                                                                                                                                    | 17/01/2019 | n/a        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0008/G   | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol   | 05/10/2018   | 19/07/2019   | SmPC, Annex II and PL   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|
| T/0007      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 11/07/2018   | 26/07/2018   | SmPC, Labelling and PL  |

<div style=\"page-break-after: always\"></div>

| II/0006             | Update of sections 4.8, 5.1 and 5.2 of the SmPC based on the supplemental Clinical Study Report for the pivotal phase 3 Study B1931022 (Study 1022) that was prepared following last patient last visit. The Package Leaflet is updated accordingly. The MAH took the opportunity to make minor editorial changes for added clarity in sections 4.2, 4.4, 4.8, 5.1, 5.3 and 6.6 of the SmPC and Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 26/07/2018   | 19/07/2019   | SmPC and PL   | The variation introduced minor amendments in both efficacy and safety results from the pivotal trial without impact on the recommendations for the use of the medicinal product. For more information please refer to the Summary of Product Characteristics.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10659 /201712 | Periodic Safety Update EU Single assessment - inotuzumab ozogamicin                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12/07/2018   | n/a          |               | PRAC Recommendation - maintenance                                                                                                                                                                                                                               |
| IB/0004             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                 | 08/01/2018   | n/a          |               |                                                                                                                                                                                                                                                                 |
| IB/0003             | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                | 08/01/2018   | n/a          |               |                                                                                                                                                                                                                                                                 |
| N/0002              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                     | 05/12/2017   | 26/07/2018   | PL            |                                                                                                                                                                                                                                                                 |
| IA/0001/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 30/10/2017   | 26/07/2018   | Annex II      |                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|